IMV (NYSE:IMV) Earns Buy Rating from Echelon Wealth Partners

IMV (NYSE:IMV)‘s stock had its “buy” rating reissued by research analysts at Echelon Wealth Partners in a report released on Tuesday, June 4th, TipRanks reports.

IMV has been the subject of several other reports. B. Riley started coverage on IMV in a research report on Wednesday, May 29th. They set a “buy” rating and a $11.00 price objective for the company. Raymond James set a $10.00 price objective on IMV and gave the stock an “outperform” rating in a research report on Monday, June 3rd. HC Wainwright set a $12.00 target price on IMV and gave the stock a “buy” rating in a research report on Friday, May 10th. Finally, Zacks Investment Research upgraded IMV from a “sell” rating to a “buy” rating and set a $4.25 target price for the company in a research report on Thursday, May 23rd. Five equities research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus target price of $9.19.

Shares of NYSE IMV traded down $0.09 during midday trading on Tuesday, reaching $2.91. 14,193 shares of the company’s stock were exchanged, compared to its average volume of 29,010. IMV has a 52-week low of $2.69 and a 52-week high of $7.07. The stock’s fifty day moving average price is $3.76.

IMV (NYSE:IMV) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.10) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.01. The firm had revenue of $0.06 million during the quarter.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of Montreal Can increased its holdings in shares of IMV by 18.5% in the first quarter. Bank of Montreal Can now owns 75,661 shares of the company’s stock valued at $304,000 after buying an additional 11,807 shares in the last quarter. Ruffer LLP acquired a new position in shares of IMV in the fourth quarter worth $31,305,000. First Manhattan Co. increased its stake in shares of IMV by 75.7% in the first quarter. First Manhattan Co. now owns 154,518 shares of the company’s stock worth $620,000 after acquiring an additional 66,550 shares during the last quarter. Hartford Financial Management Inc. increased its stake in shares of IMV by 15.0% in the fourth quarter. Hartford Financial Management Inc. now owns 26,850 shares of the company’s stock worth $139,000 after acquiring an additional 3,500 shares during the last quarter. Finally, FIL Ltd increased its stake in shares of IMV by 6.6% in the first quarter. FIL Ltd now owns 2,862,000 shares of the company’s stock worth $11,458,000 after acquiring an additional 177,000 shares during the last quarter.

About IMV

IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.

Featured Story: Inflation

Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.